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Background: Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk 
of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MAC-
Es when added to statins according to the presence of diabetes.
Methods: Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared 
ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes 
status, were included in the meta-analysis and meta-regression.
Results: A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean fol-
low-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct con-
tact (five trials). No significant heterogeneity was observed among studies (I2=14.7%, P=0.293). Ezetimibe was associated with a great-
er reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; Pheterogeneity=0.012). 
In the meta-regression analysis, the presence of diabetes was associated with a greater reduction of MACE risk when ezetimibe was add-
ed to statins (β=0.87, P=0.038).
Conclusion: Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than 
in those without diabetes. Our findings suggest that ezetimibe-statin combination therapy might be a useful strategy in patients with 
diabetes at a residual risk of MACEs.
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METHODS
Data sources, search strategy, and selection criteria
We conducted a meta-analysis based on the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [10]. Relevant studies were identified by searching 
the following data sources: MEDLINE via PubMed, Embase, 
and the Central Controlled Trials Register of the Cochrane Col-
laboration (from 1994 to December 2016). The following text 
words and medical subject headings were used without lan-
guage restriction: “ezetimibe,” “ezetimibe-simvastatin drug 
combination,” “simvastatin,” “pravastatin,” “lovastatin,” “ator-
vastatin,” “rosuvastatin,” “fluvastatin,” “pitavastatin,” and “hy-
droxymethylglutaryl-CoA reductase inhibitors.” The reference 
lists of identified studies were also scanned to find potentially 
relevant studies. Two independent authors (Y.H.L and N.H.) 
performed the literature search, data extraction, and quality as-
sessment with a standardized method, and a third reviewer 
(E.S.K.) adjudicated any discrepancies. Quality assessment was 
done using the Cochrane Collaboration’s tool for assessing the 
risk of bias in randomized trials (Supplemental Fig. S1) [11]. 
This study was approved by Institutional Review Board of Sev-
erance Hospital, Yonsei University (no. 4-2015-0637).
Data extraction and quality assessment
Standard information was extracted from published reports and 
unpublished data obtained from investigators into a spreadsheet. 
We requested and received data using a formal question sheet 
for trials with unpublished information. We collected data on 
the number of randomized patients and the occurrence of MAC-
Es in each ezetimibe and comparator group in the overall partic-
ipants, as well as in subgroups divided by the presence of diabe-
tes. Mean age, body mass index, follow-up duration, and the 
difference in the decrease of serum low density lipoprotein cho-
lesterol (LDL-C) concentration between the ezetimibe and con-
trol groups during the study were tabulated for each study. 
Statistical analysis
Relative risks (RRs) and 95% confidence intervals (CIs) were 
calculated from the event numbers, with the total number of pa-
tients as the denominator for individual studies. Heterogeneity 
across studies was estimated using the I2 statistic [12]. I2 values 
INTRODUCTION
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors) have shown efficacy in lowering cholesterol levels and 
reducing the risk of cardiovascular events in the setting of pri-
mary and secondary prevention [1,2]. Given the major contribu-
tion of cardiovascular events to morbidity and mortality in pa-
tients with diabetes, high-intensity statins are recommended for 
patients with diabetes [3,4]. However, individuals with diabetes 
have substantial residual cardiovascular risk, even when receiv-
ing statin therapy, leading to an unmet need for additional lipid-
modifying strategies [5].
Ezetimibe, a Niemann-Pick C1-like1 (NPC1L1) inhibitor, 
blocks intestinal cholesterol absorption, leading to the reduction 
of circulating cholesterol levels via a distinct mechanism from 
that of statins [6,7]. A large randomized controlled trial (RCT), 
the Improved Reduction of Outcomes: Vytorin Efficacy Interna-
tional Trial (IMPROVE-IT), demonstrated the efficacy of ezeti-
mibe-statin combination therapy on the reduction of cholesterol 
levels and major cardiovascular adverse events (MACEs) in pa-
tients who had recently experienced a myocardial infarction [8]. 
Notably, in a subgroup analysis, the beneficial effect of ezeti-
mibe added to statins on MACEs was more prominent in pa-
tients with diabetes than in patients without diabetes [8]. Results 
from another large, placebo-controlled trial investigating the ef-
ficacy of ezetimibe-statin combination therapy in reducing car-
diovascular events in chronic kidney disease patients also found 
a similar preferential effect of ezetimibe-statin combination 
therapy in patients with diabetes [9]. Given the high residual 
cardiovascular risk in patients with diabetes who are receiving 
treatment, these findings suggest that ezetimibe might provide 
additional benefits for preventing cardiovascular events, partic-
ularly in patients with diabetes. However, this potential differ-
ential effect of ezetimibe according to presence of diabetes has 
not been assessed as a primary outcome in pooled results from 
RCTs. 
In this meta-analysis, we compared the effect of ezetimibe-
statin combination therapy on MACEs to that of statins alone or 
placebo in patients with and without diabetes, based on the 
pooled results of RCTs.
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ranging from 0% to 40% were regarded as indicating no impor-
tant heterogeneity; moderate, substantial, and considerable het-
erogeneity were defined as I2 values ranging from 30% to 60%, 
50% to 90%, and 75% to 100%, respectively [13]. Weighted 
pooled treatment effects were obtained with a random-effects 
model to provide a more conservative assessment of the average 
effect size. The heterogeneity of the pooled effect between sub-
groups was calculated using the Cochran Q statistic, with the 
following formula: Q=∑[(1/variance of individual study)×(ef-
fect of individual study–effect of pooled study)]2, where vari-
ance of individual study=[(upper limit–lower limit)/(2×z)]2 
[14]. A funnel plot with symmetry testing by the Egger linear 
regression method was used to test for potential publication bias 
[15]. Sensitivity analyses were performed by repeating analyses 
while removing one study at a time using the ‘metaninf’ com-
mand (STATA). Analyses confined to statin-controlled trials 
were also performed, with the exclusion of placebo-controlled 
trials. Random-effects meta-regression models with inverse 
variance weighting were built to assess whether the presence of 
diabetes explained the variance in the estimated RR for MACEs 
observed between trials. Two-sided P values <0.05 were con-
sidered to indicate statistical significance. All statistical analyses 
were performed with STATA version 14.0 (Stata Corp., College 
Station, TX, USA). 
RESULTS
Characteristics of trials
Among the 13,220 identified records, 347 randomized, placebo 
or statin-controlled endpoint trials of ezetimibe were screened 
(Fig. 1). Studies were included if they were completed RCTs 
comparing the effects of adding ezetimibe to any statin or pla-
cebo on the incidence of MACEs and if they reported the clini-
cal outcomes in participants stratified by the presence of diabe-
tes. We also contacted investigators from eight potentially rele-
vant trials about unpublished data for incident MACEs in par-
ticipants stratified by diabetes, and received and included data 
from five of those trials. Finally, a total of seven studies, two 
with published data [8,9] and five with previously unpublished 
data that had not been analysed until our request [16-20], were 
included in the meta-analysis. The included studies enrolled 
28,191 patients (7,298 with diabetes [25.9%]) with stable angi-
na, recent acute coronary syndrome, chronic kidney disease, pe-
ripheral arterial occlusive disease, or hypercholesterolemia (Ta-
ble 1). The mean age of study subjects was 63.6 years and 
75.1% were men. The mean follow-up duration of the studies 
was approximately 5 years, according to the weighted average. 
The prevalence of diabetes varied from 22.6% to 49.7%. Only 
one study, the Study of Heart and Renal Protection (SHARP) 
trial, was a placebo-controlled study (vs. an ezetimibe-simvas-
tatin combination), whereas other trials included statin users as 
the control group. A greater LDL-C reduction (%) was shown in 
the ezetimibe and statin combination group than in the control 
group (statins or placebo), regardless of differences in the inten-
sity and doses in the statin-controlled trials. 
Outcome analysis
Fig. 2 shows the pooled association of ezetimibe combination 
therapy with MACE risk according to the presence of diabetes. 
No significant heterogeneity was observed across the trials 
(I2=14.7%, P=0.293). In the included patients, a total of 6,581 
MACEs occurred during follow-up. The definitions of MACEs 
were generally consistent among studies. Fig. 2A shows that the 
association of ezetimibe combination therapy with a lower 
MACE risk was greater in the pooled RR from subgroups with 
diabetes (RR, 0.84; 95% CI, 0.77 to 0.91) than in the pooled RR 
13,220 Identified records through database searches
347 Full text articles screened for eligibility
Among 10 relevant trials, two had published MACE 
data grouped by presence of DM.
Investigators personally contacted for eight  
unpublished data
7 Studies included in meta-analysis
Records excluded:
12,306 Non-ezetimibe study
323 Duplicated titles
244 Not RCTs
Trials excluded:
337 Studies with less than 
24 weeks of follow-up or 
sample size less than 50
Trials excluded:
3 Lack of available MACE 
data grouped by DM
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Fig. 1. Flow diagram of the literature search to identify randomized 
controlled trials (RCTs) comparing the differential effect of ezeti-
mibe combination therapy on the reduction of major adverse car-
diovascular events (MACEs) according to the presence of diabetes. 
DM, diabetes mellitus.
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from subgroups without diabetes (RR, 0.93; 95% CI, 0.85 to 
1.02; Pheterogeneity=0.012). A similar result was observed when the 
placebo-controlled study (SHARP) was excluded from the 
pooled analysis (RR, 0.86; 95% CI, 0.78 to 0.94 vs. RR, 0.97; 
95% CI, 0.92 to 1.03; Pheterogeneity=0.022) (Fig. 2B), indicating a 
statistically significant difference between the two pooled RRs 
(in the diabetes and no diabetes groups).
When all included trials were analysed by meta-regression, 
there was a trend toward a greater MACE risk reduction by 
ezetimibe combination therapy when added to statins in patients 
with diabetes compared to those without diabetes (β=0.89; 95% 
CI, 0.75 to 1.06; P=0.203). When the placebo-controlled study 
was excluded from the analysis, ezetimibe-statin combination 
therapy was associated with a greater reduction of MACE risk 
in subjects with diabetes than in those without diabetes com-
pared with statin monotherapy (β=0.87; 95% CI, 0.78 to 0.99; 
P=0.038).
Data on cancer incidence were available in three studies 
(Kouvelos, SHARP, and IMPROVE-IT) (Supplemental Fig. 
S2). The pooled RR for cancer incidence was 1.01 (95% CI, 
Fig. 2. Pooled effects of ezetimibe-statin combination therapy on 
major adverse cardiovascular events grouped by the presence of di-
abetes within studies. The test for heterogeneity between subgroups 
was significant (A) in all studies (P=0.012) and (B) after excluding 
the placebo-controlled trial (SHARP) (P=0.022). RR, risk ratio; CI, 
confidence interval; DM, diabetes mellitus; SHARP, the Study of 
Heart and Renal Protection; HEAVEN, virtual histology evaluation 
of atherosclerosis regression during atorvastatin and ezetimibe ad-
ministration study; PRECISE-IVUS, Plaque Regression With Cho-
lesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by 
Intravascular Ultrasound Study; IMPROVE-IT, the Improved Re-
duction of Outcomes: Vytorin Efficacy International Trial.
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Subtotal (I-squared=12.5%, P=0.334)
Subgroups with diabetes
West-DM
SHARP-DM
HEAVEN-DM
Suzuki-DM
Kouvelos-DM
PRECISE-IVUS-DM
IMPROVE-IT-DM
Subtotal (I-squared=0.0%, P=0.910)
Overall (I-squared=14.7%, P=0.293)
1.09 (0.27, 4.33)  0.24 47 
0.86 (0.74, 0.99) 16.12 7,176
1.04 (0.55, 1.97) 1.13 64
0.29 (0.01, 7.00) 0.04 79
0.43 (0.16, 1.17) 0.47 183
0.69 (0.38, 1.28) 1.25 142
0.98 (0.92, 1.04) 40.02 13,211
0.93 (0.85, 1.02)  59.28
0.72 (0.32, 1.62) 0.71 20
0.78 (0.64, 0.94) 10.46 2,094
0.90 (0.37, 2.20) 0.59 25
0.26 (0.03, 2.37) 0.10 78
0.78 (0.23, 2.69) 0.31 79
0.89 (0.30, 2.61) 0.40 60
0.86 (0.78, 0.94) 28.16 4,933
0.84 (0.77, 0.91) 40.72
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Study
Subgroups without diabetes
West-NonDM
HEAVEN-NonDM
Suzuki-NonDM
Kouvelos-NonDM
PRECISE-IVUS-NonDM
IMPROVE-IT-NonDM
Subtotal (I-squared=0.0%, P=0.485)
Subgroups with diabetes
West-DM
HEAVEN-DM
Suzuki-DM
Kouvelos-DM
PRECISE-IVUS-DM
IMPROVE-IT-DM
Subtotal (I-squared=0.0%, P=0.928)
Overall (I-squared=0.9%, P=0.435)
1.09 (0.27, 4.33)  0.15 47 
1.04 (0.55, 1.97) 0.70 64
0.29 (0.01, 7.00) 0.03 79
0.43 (0.16, 1.17) 0.29 183
0.69 (0.38, 1.28) 0.78 142
0.98 (0.92, 1.04) 65.93 13,211
0.97 (0.92, 1.03)  67.88
0.72 (0.32, 1.62) 0.44 20
0.90 (0.37, 2.20) 0.36 25
0.26 (0.03, 2.37) 0.06 78
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0.86 (0.78, 0.94) 32.12
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Table 2. Sensitivity Analyses for Assessing the Effects of Indi-
vidual Studies on the Pooled Risk Ratio for Major Adverse Car-
diovascular Events
Pooled RR 95% CI
Omitted study (DM)a
   West 0.84 0.77–0.91
   SHARP 0.86 0.78–0.94
   HEAVEN 0.84 0.77–0.91
   Suzuki 0.84 0.77–0.91
   Kouvelos 0.85 0.78–0.93
   PRECISE-IVUS 0.84 0.77–0.91
   IMPROVE-IT 0.77 0.65–0.92
   Combined 0.84 0.77–0.91
Omitted studies (non-DM)b
   West 0.91 0.80–1.02
   SHARP 0.97 0.91–1.03
   HEAVEN 0.91 0.81–1.02
   Suzuki 0.92 0.83–1.02
   Kouvelos 0.96 0.91–1.01
   PRECISE-IVUS 0.94 0.86–1.02
   IMPROVE-IT 0.85 0.74–0.97
   Combined 0.93 0.85–1.02
RR, risk ratio; CI, confidence interval; DM, diabetes mellitus; SHARP, 
the Study of Heart and Renal Protection; HEAVEN, Virtual histology 
evaluation of atherosclerosis regression during atorvastatin and ezeti-
mibe administration study; PRECISE-IVUS, Plaque Regression With 
Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by 
Intravascular Ultrasound Study; IMPROVE-IT, The Improved Reduc-
tion of Outcomes: Vytorin Efficacy International Trial.
aDM, subgroup with diabetes in each study; bNon-DM, subgroup with-
out diabetes in each study. 
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0.94 to 1.09; P=0.794), indicating no difference between the 
ezetimibe and control groups.
Sensitivity analysis
In the sensitivity analysis (Table 2), the meta-analyses were re-
peated after removing one study at a time. Omitting individual 
trials did not significantly affect the pooled risk, and the risk re-
duction by ezetimibe combination therapy in the diabetes group 
remained robust even after removal of the largest trial (subanal-
ysis excluding the IMPROVE-IT trial: [RR, 0.77; 95% CI, 0.65 
to 0.92 vs. RR, 0.84; 95% CI, 0.77 to 0.91; P=0.372 in the dia-
betes subgroup]; [RR, 0.85; 95% CI, 0.74 to 0.97 vs. RR, 0.93; 
95% CI, 0.85 to 1.02; P=0.278 in the non-diabetes subgroups]). 
However, the difference between the pooled RRs in the diabetes 
and non-diabetes groups did not reach statistical significance 
when the IMPROVE-IT trial was excluded (RR, 0.78; 95% CI, 
0.65 to 0.93 in the diabetes subgroup vs. RR, 0.85; 95% CI, 0.74 
to 0.97 in the non-diabetes group; Pheterogeneity=0.460), although a 
nominally consistent pattern was observed with the pooled re-
sults of the studies overall.
Publication bias
A funnel plot and Egger test of the studies did not reveal any ev-
idence of underlying publication bias for reporting MACEs 
(Supplemental Fig. S3). 
DISCUSSION
In this meta-analysis of seven RCTs, we found a differential as-
sociation of ezetimibe-statin combination therapy on MACE 
risk according to the presence of diabetes. Compared with 
statins alone, ezetimibe combination therapy reduced the risk of 
MACEs. The benefit of ezetimibe combination therapy was 
more prominent in patients with diabetes than in patients with-
out diabetes.
Recent reviews and meta-analyses of RCTs, including the 
IMPROVE-IT study, showed that ezetimibe was likely associat-
ed with a reduction of the risk of myocardial infarction and 
stroke, without affecting the risk of overall or cardiovascular 
mortality or newly-developed cancer [21,22]. However, pub-
lished reviews reported marginal cardiovascular benefits of 
ezetimibe when ezetimibe was added to statins for reducing 
nonfatal myocardial infarction and stroke (17 fewer myocardial 
infarctions and six fewer strokes per 1,000 persons treated over 
6 years) [21-24]. This uncertainty is reflected in the absence of a 
consensus regarding ezetimibe in international guidelines. The 
2013 treatment guidelines of the American Heart Association/
American College of Cardiology (AHA/ACC) focused on statin 
monotherapy and did not suggest considering second-line drugs, 
including ezetimibe, as a treatment option based on a lack of 
strong evidence [4]. However, European and Korean guidelines 
for the management of dyslipidaemia permit the use of ezeti-
mibe as a second-line therapy in association with statins when 
the therapeutic goal is not met despite maximal tolerated statin 
doses or in subjects intolerant to statins [25,26]. In line with 
newer evidence, the 2016 AHA/ACC updates on cholesterol 
treatment commented that second-line cholesterol-lowering 
drugs can be used to meet LDL-C treatment targets, at least in 
limited circumstances [27]. Given the current evidence of the 
ability of ezetimibe to prevent cardiovascular events, it is im-
portant to identify the specific populations that might benefit the 
most from ezetimibe. However, no reviews or meta-analyses 
have primarily focused on the differential effect of ezetimibe 
according to the presence of diabetes. In this study, the pooled 
results of RCTs with a statin control arm showed that patients 
with diabetes experienced a greater benefit from ezetimibe-
statin combination therapy than patients without diabetes, indi-
cating that the presence of diabetes might be a potential indica-
tion for adding ezetimibe to the therapeutic regimen of patients 
with high residual risk.
Several biological and clinical findings support the beneficial 
effect of ezetimibe in diabetes. Patients with a higher risk of 
cardiovascular events experience greater benefits when ezeti-
mibe is added to statins, as shown in a previous review [22]. Pa-
tients with diabetes are more likely to have a higher cardiovas-
cular risk at baseline than patients without diabetes, which 
might lead to ezetimibe exerting a positive effect in patients 
with diabetes [8]. Furthermore, pathologic enhancement of 
NPC1L1 expression, a direct target of ezetimibe, has been re-
ported in patients with diabetes [28,29]. Indeed, ezetimibe was 
associated with greater decreases in LDL-C and non-high den-
sity cholesterol levels in patients with diabetes than in those 
without diabetes [30,31]. In addition to its favourable effects on 
the lipid profile of individuals with diabetes, ezetimibe combi-
nation therapy was associated with improvements in insulin 
sensitivity and plasma adiponectin levels compared with statin 
monotherapy in patients with diabetes [32]. In the Plaque Re-
gression With Cholesterol Absorption Inhibitor or Synthesis In-
hibitor Evaluated by Intravascular Ultrasound Study (PRE-
CISE-IVUS) trial, which was included in this analysis, the 
greater reduction of atherosclerotic plaque progression by ezeti-
mibe could not be entirely explained by its cholesterol-lowering 
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effects [20]. Anti-inflammatory effects, reduction of the plant 
sterol ratio, inhibition of smooth muscle cell proliferation, and 
antiplatelet effects have been proposed as potential mechanisms 
underlying the cardiovascular benefit of ezetimibe [33-36]. Tak-
en together, these pieces of evidence suggest that ezetimibe 
combination therapy might have a protective effect on cardio-
vascular outcomes in patients with diabetes, possibly through its 
lipid-lowering effects or through a pleiotropic effect; however, 
the mechanisms of the effects of ezetimibe must be confirmed 
in further studies.
Concerns regarding increased cancer-related mortality associ-
ated with ezetimibe use have been raised. According to a pooled 
analysis of three large trials (Simvastatin in Aortic Stenosis 
[SEAS], SHARP, and IMPROVE-IT), ezetimibe use was asso-
ciated with a nominally increased risk of cancer-related mortali-
ty (risk ratio, 1.45; 99% CI, 1.02 to 2.05; uncorrected P=0.007) 
[37,38]. However, the authors argued that this result might have 
been due to chance, rather than being a true finding, because a 
parallel increase in the cancer incidence was not found in the 
combined analysis. In our study, we also observed no associa-
tion of ezetimibe use with cancer incidence when SHARP, IM-
PROVE-IT, and the study by Kouvelos et al. [18] were pooled 
together, similarly to the meta-analysis performed by Savarese 
et al. [21]. Although monitoring for mortality due to cancer 
should be continued in large prospective trials, our findings sup-
port the current consensus that ezetimibe is most likely not as-
sociated with an increased risk of cancer incidence.
Our study is limited by the small number of eligible RCTs, 
with a single study representing the majority of enrolled pa-
tients. Although we intentionally only analysed RCTs to mini-
mize heterogeneity, it is possible that excluding observational 
studies with large numbers of subjects and longer follow-up du-
rations might have led to an underestimation of the effect size of 
ezetimibe. Surrogate outcomes were not analysed in this study. 
Although we analysed LDL-C levels according to the treatment 
groups, we could not obtain changes in the LDL-C level for 
each study stratified by diabetes. A composite endpoint, MAC-
Es, was analysed instead of individual outcomes due to the lack 
of data stratified by the presence of diabetes, although the scope 
of this study was to evaluate the heterogeneity of the effects of 
ezetimibe on cardiovascular events between individuals with 
diabetes and those without diabetes. The studies that remained 
after excluding the SHARP and the IMPROVE-IT trials in our 
study might have been underpowered for detecting a significant 
additive cardioprotective effect of ezetimibe combination thera-
py between the diabetes and non-diabetes groups. Meanwhile, a 
previous meta-analysis of the effects of ezetimibe emphasized 
that including large studies such as SHARP or IMPROVE-IT in 
the pooled outcome analyses led to a significantly larger sample 
of patients, with greater representativeness of real-world pa-
tients, when compared to a meta-analysis performed without the 
results from large trials [21,23]. Furthermore, our study provid-
ed a comparison of the pooled risk of cardiovascular outcomes 
between diabetes and no diabetes groups, based on data that 
were collected by direct contact. Therefore, we believe that this 
analysis contributes some novel information on the interaction 
of the effects of ezetimibe with the presence of diabetes, al-
though further prospective trials are needed to validate this pos-
sibility.
In conclusion, the pooled results of RCTs showed that ezeti-
mibe was associated with a greater reduction of MACEs in pa-
tients with diabetes than in those without diabetes. This differ-
ential effect of ezetimibe was robust across the trials. Given the 
current evidence regarding ezetimibe as a second-line lipid-
lowering agent, ezetimibe-statin combination therapy might 
provide a feasible treatment option to combat residual cardio-
vascular risk in patients with diabetes who are intolerant or re-
fractory to statin therapy.
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